Answers are grounded in this paper and cite their sources.
Chronic kidney disease is a complicated, multifaceted disorder with multiple complications. Limited studies have assessed the potential role of Apelin in the assessment of cardiac outcomes in patients with chronic kidney disease. Herein, we performed a prospective case-control study including 70 patients with CKD. Patients on chronic dialysis were excluded. Laboratory examinations, including serum Apelin levels, were performed. Moreover, the patients were monitored for 18 months. The mean value of apelin was lower in CKD patients than in the control group (378.86 pg/ml compared to 663.93 pg/ml, p<0.0001). Cardiovascular complications were more frequent in CKD patients than in the control group (38.6% as compared to 6.7%, respectively, p=0.017). Furthermore, serum apelin levels were lower in patients with CVD complications (317.3 ± 73.9 pg/ml, compared to 417.5 ±51.3 pg/ml, p<0.001). Multivariate regression analysis revealed that only Apelin levels were a significant predictor of CVD complications with a negative correlation (Odds ratio 0.96, 95%CI [0.95-0.99], p=0.001) Subsequently, we found that only apelin had a significant correlation with the occurrence of cardiovascular complications in patients with CKD. The lower the levels of apelin, the higher the incidence of cardiovascular complications.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: